Details of the Drug

General Information of Drug (ID: DM3BVAE)

Drug Name
Obinutuzumab
Synonyms GA101/RG7159
Indication
Disease Entry ICD 11 Status REF
Chronic lymphocytic leukaemia 2A82.0 Approved [1], [2]
Haematological malignancy 2B33.Y Phase 1 [3]
Drug Type
Antibody
ADMET Property
Half-life
The concentration or amount of drug in body reduced by one-half in 28.4 days [4]
Metabolism
The drug is not metabolised [5]
Vd
The volume of distribution (Vd) of drug is 3.8 L [6]
Cross-matching ID
DrugBank ID
DB08935
TTD ID
D0S8WA

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Leukocyte surface antigen Leu-16 (CD20) TTUE541 CD20_HUMAN Not Available [7]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Obinutuzumab (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Obinutuzumab and Siponimod. Multiple sclerosis [8A40] [16]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Obinutuzumab and Ocrelizumab. Multiple sclerosis [8A40] [17]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Obinutuzumab and Ozanimod. Multiple sclerosis [8A40] [18]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Obinutuzumab when combined with Anthrax vaccine. Sepsis [1G40-1G41] [19]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6941).
2 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
6 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
7 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2628).
8 Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20. Mol Immunol. 2009 Jul;46(11-12):2419-23.
9 [Contribution of radioimmunotherapy to the treatment of lymphoma]. Ann Pharm Fr. 2008 Nov-Dec;66(5-6):300-8.
10 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
11 Clinical pipeline report, company report or official report of Genentech (2009).
12 Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
13 Clinical pipeline report, company report or official report of Roche (2009).
14 Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl. 2020 Aug 28;6(1):28.
15 Clinical pipeline report, company report or official report of Genmab.
16 Cerner Multum, Inc. "Australian Product Information.".
17 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
18 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
19 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]